Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Royer

Showing results (121-130 of 131) with videos related to

Pageof 14
Sort By:
British Journal of Cancer|December 17, 2011
Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic studyB Royer, E Kalbacher, S Onteniente, et al.
British Journal of Cancer|July 20, 2000
Evidence for susceptibility genes to familial Wilms tumour in addition to WT1, FWT1 and FWT2E A Rapley, R Barfoot, C Bonaïti-Pellié, et al.
Kidney International|June 2, 1998
Spectrum of early onset nephrotic syndrome associated with WT1 missense mutationsV Schumacher, K Schärer, E Wühl, et al.
La Revue De Medecine Interne|October 30, 2016
[Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study]E Weber, G Moulis, M Mahévas, et al.
Kidney International|August 17, 2006
Recessive missense mutations in LAMB2 expand the clinical spectrum of LAMB2-associated disordersK Hasselbacher, R C Wiggins, V Matejas, et al.
Leukemia|July 30, 2011
Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experienceH Avet-Loiseau, M Roussel, L Campion, et al.
Leukemia|April 6, 2013
Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myelomaX Leleu, G Fouquet, B Hebraud, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 27, 2024
Real-Life Management of Patients Aged 80 Years Old and Over With Multiple Myeloma: Results of the EMMY CohortT Chalopin, M Macro, O Decaux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2016
Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myelomaG Fouquet, B Pegourie, M Macro, et al.
Journal of Medical Genetics|August 3, 2006
STK11 status and intussusception risk in Peutz-Jeghers syndromeN Hearle, V Schumacher, F H Menko, et al.
Pageof 14

Showing results (121-130 of 131) with videos related to

Sort By:
Pageof 14
British Journal of Cancer|December 17, 2011
Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic studyB Royer, E Kalbacher, S Onteniente, et al.
British Journal of Cancer|July 20, 2000
Evidence for susceptibility genes to familial Wilms tumour in addition to WT1, FWT1 and FWT2E A Rapley, R Barfoot, C Bonaïti-Pellié, et al.
Kidney International|June 2, 1998
Spectrum of early onset nephrotic syndrome associated with WT1 missense mutationsV Schumacher, K Schärer, E Wühl, et al.
La Revue De Medecine Interne|October 30, 2016
[Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study]E Weber, G Moulis, M Mahévas, et al.
Kidney International|August 17, 2006
Recessive missense mutations in LAMB2 expand the clinical spectrum of LAMB2-associated disordersK Hasselbacher, R C Wiggins, V Matejas, et al.
Leukemia|July 30, 2011
Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experienceH Avet-Loiseau, M Roussel, L Campion, et al.
Leukemia|April 6, 2013
Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myelomaX Leleu, G Fouquet, B Hebraud, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 27, 2024
Real-Life Management of Patients Aged 80 Years Old and Over With Multiple Myeloma: Results of the EMMY CohortT Chalopin, M Macro, O Decaux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2016
Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myelomaG Fouquet, B Pegourie, M Macro, et al.
Journal of Medical Genetics|August 3, 2006
STK11 status and intussusception risk in Peutz-Jeghers syndromeN Hearle, V Schumacher, F H Menko, et al.
Pageof 14